Prosecution Insights
Last updated: November 20, 2026
Application No. 18/167,295

DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER

Final Rejection §112§DOUBLEPATENT
Filed
Feb 10, 2023
Priority
Aug 12, 2020 — provisional 63/064,884 +1 more
Examiner
AEDER, SEAN E
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Genentech Inc.
OA Round
2 (Final)
57%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
819 granted / 1438 resolved
-3.0% vs TC avg
Strong +20% interview lift
Without
With
+19.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
88 currently pending
Career history
1526
Total Applications
across all art units

Statute-Specific Performance

§101
14.7%
-25.3% vs TC avg
§103
26.4%
-13.6% vs TC avg
§102
17.2%
-22.8% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1438 resolved cases

Office Action

§112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action The Amendments and Remarks filed 10/29/26 in response to the Office Action of 4/29/26 are acknowledged and have been entered. Claim 46 has been added by Applicant. Claims 14-16, 20-28, 33-36, 38, and 46 are pending. Claims 14-16, 20-23, 27, 33-36, and 38 have been amended by Applicant. Claims 14-16, 20-28, 33-36, 38, and 46 are currently under examination. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The following Office Action contains NEW GROUNDS of rejections Necessitated by Amendments. Rejections Withdrawn All previous rejections are withdrawn. Claim Objections Claim 20 is objected to because of apparent typographical issues. It appears “individual who” at the line 2 of the claim should be replaced with “individual, wherein the individual” to clarify who has been determined to have a recited PRS. Further, there appears to be a missing comma after the word “cancer” at line 5 of the claim. Proper correction is required. Claims 21-26, 33-36, and 38 are objected to for being dependent upon an objected claim. New Rejections Claim Rejections - 35 USC § 112 Claims 27-28 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 27-28 each recite “…wherein the sample is….” There is insufficient antecedent basis for “the sample” in the claims. Double Patenting Claim 14-16 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 12183434 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the patent claims are directed to species of the instant claims. Claims 14-16 and 46 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 87-106 of copending Application No. 18/941251 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because copending claims are directed to species of instant claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN E AEDER whose telephone number is (571)272-8787. The examiner can normally be reached M-F 9am-6pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571)270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SEAN E AEDER/Primary Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Feb 10, 2023
Application Filed
Mar 23, 2026
Non-Final Rejection (signed) — §112, §DOUBLEPATENT
Apr 29, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT
Oct 29, 2026
Response Filed
Nov 12, 2026
Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799539
METHODS FOR IDENTIFYING AND TREATING HIGH-PLASTICITY CELL STATE DRIVING TUMOR PROGRESSION IN LUNG CANCER
4y 9m to grant Granted Nov 17, 2026
Patent 12774326
Agent for Preventing or Treating Frontotemporal Lobar Degeneration
3y 4m to grant Granted Oct 27, 2026
Patent 12758582
ANTI-CD33 ANTIBODIES AND USES THEREOF
4y 0m to grant Granted Oct 13, 2026
Patent 12760124
TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS
2y 8m to grant Granted Oct 13, 2026
Patent 12746272
METHOD OF TREATMENT OF CANCER OR TUMOUR
3y 8m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
57%
Grant Probability
77%
With Interview (+19.8%)
3y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1438 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month